Skip to content

Biomarker of Diabetic Retinopathy

Biomarker of Diabetic Retinopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05079399
Enrollment
192
Registered
2021-10-15
Start date
2022-01-01
Completion date
2027-06-30
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Brief summary

Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen/nutrient deficiency. Ultimately affecting the normal vision. There is no known marker that will provide information on the health status of retinal blood vessels. Using highly specialized cells in the blood, this study will try to discover a marker of DR.

Interventions

OTHERBlood draw

Blood samples will be collected via venipuncture

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Ability to cooperate with imaging procedures. * Health status: established type 2 diabetes * No history of panretinal photocoagulation (PRP) * No history of treatment with intravitreal agents for past 12 months

Exclusion criteria

* Previous or current malignancy * Acute or chronic infection (HIV, hepatitis B or C, tuberculosis) * Cerebral vascular accident or cerebral vascular procedure * Current pregnancy * History of organ transplantation * Presence of a graft (to avoid any effect of the graft) * History of previous vitrectomy * Subjects with a history of age-related macular degeneration age-related macular degeneration (AMD), glaucoma, uveitis, and branched or central vein occlusion.

Design outcomes

Primary

MeasureTime frame
mRNA and miRNA sequencing of circulating angiogenic cells isolated from study participantsBaseline and change in RNA signature in follow up visit (between 3-5 years)
Surface marker expression of inflammatory markers using flow cytometryBaseline
miRNA expressionBaseline
Epigenetic changes in circulating angiogenic cells with different severities of diabetic retinopathyBaseline

Secondary

MeasureTime frameDescription
Early Treatment Diabetic Retinopathy Study (ETDRS) clinical scoring in wide-field fundus photographyBaseline and follow up visit (between 3-5 years)The scoring will be between 10 (no retinopathy) and 85 (advanced proliferative diabetic retinopathy). Higher score means worst outcome
Presence or absence of neovascularization and total area of non-perfusion in fluorescein angiography (FA)Baseline and follow up visit (between 3-5 years)
Change in vessel density in optical coherence tomography angiography (OCT-A)Baseline and follow up visit (between 3-5 years)
Change in retinal thickness in optical coherence tomography angiography (OCT-A)Baseline and follow up visit (between 3-5 years)

Countries

United States

Contacts

CONTACTAshay D Bhatwadekar, PhD, RPh
abhatwad@iupui.edu3172785075
CONTACTAmir R Hajrasouliha, MD
amhajras@iu.edu3179441154

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026